Equillium Files 10-Q for Q1 2025

Ticker: EQ · Form: 10-Q · Filed: May 14, 2025 · CIK: 1746466

Equillium, INC. 10-Q Filing Summary
FieldDetail
CompanyEquillium, INC. (EQ)
Form Type10-Q
Filed DateMay 14, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, pharmaceutical, financial-report

TL;DR

Equillium's Q1 2025 10-Q is in. Check Ono and Syngene deal updates.

AI Summary

Equillium, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data and business activities are reported, including details related to agreements with Ono Pharmaceutical Co., Ltd. and Syngene International Limited.

Why It Matters

This filing provides investors with an update on Equillium's financial health and operational progress for the first quarter of 2025, including details on significant agreements.

Risk Assessment

Risk Level: medium — The company operates in the pharmaceutical sector, which is inherently high-risk due to R&D, regulatory hurdles, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period for this 10-Q filing is March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 14, 2025.

Which company is the primary filer of this document?

Equillium, Inc. is the primary filer of this document.

Are there any specific agreements mentioned in the filing details?

Yes, the filing details mention an Asset Purchase Agreement with Ono Pharmaceutical Co., Ltd. and a Master Services Agreement with Syngene International Limited.

What is Equillium, Inc.'s Standard Industrial Classification code?

Equillium, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Equillium, Inc. (EQ).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing